<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Northeastern_Boston_Description skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Northeastern Boston/Description</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="wrapper"><DIV id="sidebar"><DIV id="bar_title" class="title"><A href="https://2015.igem.org/Team:Northeastern_Boston">
	      Northeastern</A></DIV><UL class="nav"><LI><A id="a-home" href="https://2015.igem.org/Team:Northeastern_Boston">Home</A></LI><LI><A id="a-team" href="https://2015.igem.org/Team:Northeastern_Boston/Attributions">Team</A></LI><LI><A id="a-project" class="active">Project</A></LI><DIV class="sub-nav__container"><LI id="a-parts" class="sub-nav__parent"><A>
		        	Parts
		        	</A></LI><DIV class="sub-nav__children hidden"><LI class="sub-nav__child"><A href="https://2015.igem.org/Team:Northeastern_Boston/BasicParts">Basic &amp; Composite</A></LI><LI class="sub-nav__child"><A href="https://2015.igem.org/Team:Northeastern_Boston/Design">Expression Plasmid</A></LI></DIV></DIV><DIV class="sub-nav__container"><LI id="a-notebook" class="sub-nav__parent"><A>
		        	Notebook 
		        	</A></LI><DIV class="sub-nav__children hidden"><LI class="sub-nav__child"><A href="https://2015.igem.org/Team:Northeastern_Boston/notebook">Protocols</A></LI><LI class="sub-nav__child"><A href="https://2015.igem.org/Team:Northeastern_Boston/Workflow">Workflow</A></LI></DIV></DIV><DIV class="sub-nav__container"><LI id="a-humanpractices" class="sub-nav__parent"><A>
		        	Human Practices
		        	</A></LI><DIV class="sub-nav__children hidden"><LI class="sub-nav__child"><A href="https://2015.igem.org/Team:Northeastern_Boston/Collaborations">Collaborations</A></LI><LI class="sub-nav__child"><A href="https://2015.igem.org/Team:Northeastern_Boston/Practices">Outreach</A></LI><LI class="sub-nav__child"><A href="https://2015.igem.org/Team:Northeastern_Boston/Written_Investigation">Written Investigation</A></LI></DIV></DIV><LI><A id="a-safety" href="https://2015.igem.org/Team:Northeastern_Boston/safety">Safety</A></LI><LI><A id="a-measurement" href="https://2015.igem.org/Team:Northeastern_Boston/measurement">Interlab</A></LI></UL></DIV><DIV class="content"><DIV id="page-header__project" class="page-header"><H1 class="page-header__title" align="left" style="border-width:0">OUR PROJECT</H1></DIV><DIV class="Notebook"><DIV class="minimal-dropdown__container"><DIV class="minimal-dropdown__header"><H2 class="minimal-dropdown__title">Overview</H2></DIV><DIV class="minimal-dropdown__content hidden"><P><I>&quot;Dr. George D. Yancopoulos, chief scientific officer of Regeneron,
			      said the crisis had pointed up shortcomings in biodefense. “Nobody is
			      really prepared,” he said. “Nobody in the world has rapid response
			      capabilities.”</I>—New York Times, January 2015</P><P>Humans need improved methods for making therapeutic antibodies.
			      Producing these complex proteins is hard but important; the 2014 Ebola
			      Outbreak illustrates the urgency. In response, we propose the use of
			      microalgae as a widescale antibody production platform. Microalgae have
			      all the benefits of higher-level plants but scale faster and are easier
			      to process. Furthermore, from a holistic point of view, microalgae are an
			      ideal chassis; their primary carbon source is CO<SUB>2</SUB> and they are
			      unlikely to harbor mammalian pathogens.</P></DIV></DIV><DIV class="minimal-dropdown__container"><DIV class="minimal-dropdown__header"><H2 class="minimal-dropdown__title">The Need</H2></DIV><DIV class="minimal-dropdown__content hidden"><P><I>&quot;I rate the chance of a nuclear war within my lifetime as being
			      fairly low. I rate the chance of a widespread epidemic, far worse than
			      Ebola, in my lifetime, as well over 50 percent.&quot;</I> —Bill
			      Gates</P>Epidemic spread modeling by Brockmann's group
			      at Humbolt University. (http://rocs.hu-berlin.de/). This model shows the
			      spread of a theoretical outbreak of a particularly contagious pathogen in
			      Atlanta, GA. The spread is over 60 days.<P>With the most recent Ebola Outbreak, over 28 thousand were infected by
			      the deadly pathogen and an estimated 11 thousand died. Meanwhile, a
			      potent anti-Ebola antibody cocktail, ZMapp, was going through preclinical
			      studies. In a study where 18 heavily Ebola infected monkeys were treated with
			      ZMapp, all 18 survived, including several in the hemorrhaging stage of
			      the disease. Given the timing and urgent need, ZMapp was approved for use
			      in humans.[<A href="http://www.nature.com/nature/journal/vnfv/ncurrent/full/nature13777.html?utm_content=bufferb2c23&amp;utm_medium=social&amp;utm_source=twitter.com&amp;utm_campaign=buffer" target="_blank">1</A>]</P><P>Antibodies are unique and powerful tools for eliminating pathogens.
			      Unfortunately,
			      ZMapp’s utility was hindered by lack of supply, not an apparent inability
			      to neutralize the virus (as illustrated by the Rhesus model). Only 7
			      doses were available throughout the Ebola Outbreak despite infection
			      rates in the thousands. Ultimately, it represents an absence of rapid antibody production capabilities.</P><P>A proposed solution was the tobacco plant. A relatively
			      well-understood and engineered organism, it was the method for making
			      ZMapp. Producers agrobacterium containing the
			      DNA for the therapeutic antibody into the plant leaves by vacuum infiltration. The plants grow and the antibody is
			      purified from the plant cell lysate. In theory, this is a quick and
			      inexpensive method for rapidly producing lots of antibody, dependent upon
			      arable land rather than high-sterility CHO vats. [<A href="http://www.sciencedirect.com/science/article/pii/S0006291X03013354" target="_blank">2</A>] In practice, it is
			      not.</P></DIV></DIV><DIV class="minimal-dropdown__container"><DIV class="minimal-dropdown__header"><H2 class="minimal-dropdown__title">Some Solutions</H2></DIV><DIV class="minimal-dropdown__content hidden"><P>It might one day be possible to make drugs entirely without cells.
			      Protein-producing gels or other systems could produce drugs economically
			      in vitro avoiding the inherent biological complexity and metabolic needs
			      of living organisms. [<A href="http://www.nature.com/nmat/journal/v8/n5/pdf/nmat2419.pdf" target="_blank">3,</A><A href="http://www.sciencedirect.com/science/article/pii/S1389172314001509" target="_blank">4</A>]</P><P>It might, alternatively, be possible to inject the mRNA of a desired
			      antibody directly, thereby offloading the antibody production to the
			      patient rather than delivering a bolus of externally produced antibody.
			      Moderna, for example, has developed synthetic mRNA that codes for
			      polypeptides while avoiding immune-surveillance (and therefore
			      elimination). It’s currently unclear how this mRNA will be targeted to
			      delivery into B cells, and for how long the B cells will continue to
			      produce antibodies. This approach, offloading manufacturing of antibodies
			      to the patient, has been extensively researched in the context of AIDS.
			      [<A href="http://www.ncbi.nlm.nih.gov/pubmed/8864752" target="_blank">5</A>, <A href="http://www.mdpi.com/1999-4915/6/2/428/html" target="_blank">6</A>, <A href="http://www.nature.com/ni/journal/v14/n1/full/ni.2480.html" target="_blank">7</A>]</P><P>In might be possible to design synthetic bacteria (like Synlogic) for
			      the gut that produce Nanobodies (small enough to be produced in bacteria
			      and lacking complex di-sulfide bonds). These pathogen targeting
			      nanobodies might prove capable of reaching the circulatory system after
			      being turned on by an exogenous transcription factor, however, these
			      nanobodies might still face the complication of improper glycosylation
			      and immune clearance. [<A href="http://europepmc.org/abstract/med/19876789" target="_blank">8</A>]</P><P>Despite the volume of researchers working on futuristic solutions,
			      recombinant antibodies are known to work. They are less theoretical and
			      more a problem of logistics. And logistically, antibodies from Chinese
			      hamster ovary cells or tobacco plants never materialized during the 2014
			      Ebola Outbreak. So the question becomes: can microalgae produce properly
			      folded antibodies at a high enough concentration and at a cheap enough
			      cost to warrant their use as a widescale antibody production platform? Given the need and potential benefits, we believe it warrants additional research.</P></DIV></DIV><DIV class="minimal-dropdown__container"><DIV class="minimal-dropdown__header"><H2 class="minimal-dropdown__title">A Green Safety Net</H2></DIV><DIV class="minimal-dropdown__content hidden"><P>Within each of us (health and medication depending) is an adaptive
			      immune system. A major cell in this system is the B Cell. An immunocompetent
			      B cell is covered in B cell receptors (BCRs). These BCRs respond to
			      non-self antigens. When a foreign antigen binds to a BCR, it activates
			      the B cell to turn into a plasma B cell, dedicated to producing specific
			      antibodies against the antigen that triggered its
			      response.</P><P>Some of the plasma B cells enter secondary lymphoid organs, otherwise
			      known as “germinal centers.” Here, B cells undergo rapid mutation so that
			      the selected-for plasma B cell population produces higher affinity
			      antibodies. The resulting plasma B cells begin leave the germinal center
			      to pump out high levels of antibody into the bloodstream. [<A href="https://www.rndsystems.com/research-area/b-cells" target="_blank">9]</A></P><P>This is what the human species lacks with macro-level infrastructure.
			      Hospitals and care-centers act as an innate response, responding in the
			      emergence of a contagion to quarantine the sick and provide nourishment.
			      They are not designed with the capability to rapidly adapt and attack the
			      pathogen. Drugs for human treatment undergo rigorous FDA
			      review before approval; the average inception to market timeline for an
			      FDA approved drug is 12 years (note: this is after the drug has been
			      developed). This is too long for rapid drug turnaround and represents a
			      significant threat to human health.</P>A hypothetical map of distributed
			      algae-antibody production facilities. Orange dots are
			      existing facilities that could be repurposed. Yellow dots are
			      hypothetical potential power plant algae hybrid facilities. They are
			      smaller in scale but repurposable in a time of need. Green dots are
			      potential large sized facilities. These too could produce commodity
			      goods, like food for livestock or subsidized biofuel, until needed for
			      antibody production.<P>In industrialized countries with significant carbon taxes, like the UK
			      and Australia, microalgae facilities might become commonplace alongside
			      power plants. Sapphire Energy, Sunomix, and Solazyme have demonstrated
			      the market potential of microalgae products. It would be strategic to
			      further distribute algae plants near heavily populated areas. Were a
			      pandemic to occur, these facilities could expunge their
			      commodity-producing microalgae and replace it with a high antibody
			      producing strain of microalgae, like recombinant <I>Chlamydomonas
			      reinhardtii</I> or <I>Phaeodactylum tricornutum</I>.</P></DIV></DIV><DIV class="minimal-dropdown__container"><DIV class="minimal-dropdown__header"><H2 class="minimal-dropdown__title">Cost/Benefit</H2></DIV><DIV class="minimal-dropdown__content hidden"><P>The true benefit of using microalgae for antibody production is the
			      lower fixed cost of facilities.</P><P>CHO facilities, on average, cost around $200M for 80,000L. A similarly
			      sized algae facility at 15,000L would cost an estimated $1.3M. With
			      economies of scale, algae production facilities become significantly
			      cheaper. $1B would be a 14 Billion Liter algae farm (5,500 acres)
			      according to one techno-economic analysis [<A href="http://www.sciencedirect.com/science/article/pii/S2211926413001008" target="_blank">10</A>].</P><P>The biggest challenge for microalgae will be improved productivity.
			      Because of fixed and variable costs, microaglae will not need to be 100%
			      as productive as CHO's (extremely unlikely in the near-term, given the
			      amount of research and time invested in CHO's), however, they will need
			      to improve 1-2 magnitudes over current levels. CHOs are far and beyond
			      the most efficient antibody producers, with some strains now exceeding
			      grams of product per liter of culture media. Furthermore, they are
			      entrenched in the industry: 61 of the 90 therapeutic proteins produced in
			      mammalian cells come from CHO's (Rader, 2015. Bioprocessing Journal).
			      Furthermore, of the 174 recombinant FDA approved drugs on the market,
			      only one is made by plant cells (Elelyso from carrot cell
			      culture).</P><P>An encouraging number is maximum biomass. Microalgae can quickly reach
			      high densities, with some culture conditions allowing biomass in excess
			      of 10g/L. With a higher cellular density, and significantly larger scales
			      for the same investment, microalgae may soon contend with CHO's.</P><P>Sources: <A href="https://static.igem.org/mediawiki/2015/4/46/Screen_Shot_2015-09-10_at_7.44.36_PM.png" target="_blank">Facility Volume vs Cost</A>, <A href="https://static.igem.org/mediawiki/2015/9/96/Screen_Shot_2015-09-10_at_7.44.56_PM.png" target="_blank">Productivity</A>, and <A href="https://static.igem.org/mediawiki/2015/e/e1/Screen_Shot_2015-09-10_at_7.45.03_PM.png" target="_blank">Cell Density</A></P></DIV></DIV><DIV class="minimal-dropdown__container"><DIV class="minimal-dropdown__header"><H2 class="minimal-dropdown__title">Approach</H2></DIV><DIV class="minimal-dropdown__content hidden"><P>Northeastern 2015 set out for the highest protein expression possible. The rationale for this approach was to counteract the typically low nuclear expression levels of heterologous proteins in <I>C. reinhardtii</I>. Therefore, the designed novel plasmid used <A href="http://parts.igem.org/Part:BBa_K1547005" target="_blank">pPsaD</A>, a very strong promoter. While it was possible to make all the parts, the Gibson repeatedly failed.</P><P>We then shifted towards adaption of a plasmid from the Chlamy Collection: pOpt_mVenus. By surrounding the first promoter with the iGEM prefix and suffix, we created an iGEM compatible protein expression <A href="https://2015.igem.org/Team:Northeastern_Boston/Design" target="_blank">plasmid</A>. In this way, teams can remove the suffix and replace it with a codon-optimized coding sequence for heterologous proteins of interest, or remove the promoter region entirely, testing alternate promoters and coding sequences upstream of a hygromycin B selection cassette.</P><P>Genetic engineering of microalgae is not new. <I>C. reinhardtii</I>, in particular, has been explored as a platform for heterologous proteins for years but to a far lesser extent than mammalian cells or higher-order plants. Although they're difficult to engineer, microalgae are poised to disrupt biofuel, agriculture, and pharmaceuticals. With their primary reliance on CO<SUB>2</SUB> and their capacity for producing complex proteins, microalgae like <I>C. reinhardtii</I> represent the chassis of the future.</P></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>